{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:04:20Z","timestamp":1790697860591,"version":"4.1.0"},"reference-count":17,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","award":["P30EY025585(BA-A)"],"award-info":[{"award-number":["P30EY025585(BA-A)"]}],"id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of VitreoRetinal Diseases"],"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To describe how 15-letter loss of visual acuity (VA) in patients with neovascular age-related macular degeneration (nAMD) results in transient fluctuations in vision. In addition, to compare recoverability of letter loss in patients treated with antivascular endothelial growth factor (anti-VEGF) with untreated patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Patients with previously untreated nAMD in the Comparisons of AMD Treatments Trials were assigned to transient and nontransient groups based on recovery of baseline best-corrected VA within 8 weeks. Magnitude of recoverable letter loss was modeled via linear regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Two hundred fifty-three of 1018 patients (25%) experienced 15-letter loss: 68 transient (7%) and 185 nontransient (18%). Two-year outcomes were better without 15-letter loss (+12 letters, 95% CI, 11-13, n = 772) compared with transient 15-letter loss (+0.4 letters, 95% CI, \u22124 to 5) and nontransient 15-letter loss (\u221214 letters, 95% CI, \u221217 to \u221212). Nontransient losses up to \u22122.5 letters were expected to be recoverable (95% CI, \u22126.0 to 1.0). Fifteen-letter loss was associated with smoking (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .02) and poor nontransient outcomes with higher blood pressure (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .04).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Patients experiencing transient and nontransient 15-letter loss differed significantly in outcomes. Nontransient losses were not expected to be recoverable. These findings may help guide the selection of measures in clinical trial design.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/24741264261472092","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T07:01:46Z","timestamp":1786604506000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Incidence and Recovery of 15-Letter Loss of Visual Acuity in Patients With Neovascular Age-Related Macular Degeneration on Antivascular Endothelial Growth Factor Therapy"],"prefix":"10.1177","author":[{"given":"Calvin X.","family":"Taylor","sequence":"first","affiliation":[{"name":"Case Western Reserve University School of Medicine, Cleveland, OH, USA"},{"name":"Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA"},{"name":"San Antonio Uniformed Services Health Education Consortium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2577-108X","authenticated-orcid":false,"given":"Hayden","family":"Reed","sequence":"additional","affiliation":[{"name":"Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA"},{"name":"A.T. Still University School of Osteopathic Medicine, Mesa, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine E.","family":"Talcott","sequence":"additional","affiliation":[{"name":"Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA"},{"name":"Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland OH, USA"},{"name":"Cleveland Clinic Cole Eye Institute, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5859-8162","authenticated-orcid":false,"given":"Rishi P.","family":"Singh","sequence":"additional","affiliation":[{"name":"Mass Eye and Ear, Mass General Brigham, Boston, MA, USA"},{"name":"Department of Ophthalmology, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"e_1_3_3_2_2","volume-title":"A Systematic Review of Intravitreal Bevacizumab for the Treatment of Diabetic Macular Edema","author":"Fortin P","year":"2012","unstructured":"Fortin P, Mintzes B, Innes M. A Systematic Review of Intravitreal Bevacizumab for the Treatment of Diabetic Macular Edema. Canadian Agency for Drugs and Technologies in Health; 2012: Appendix 2."},{"key":"e_1_3_3_3_2","volume-title":"Neovascular Age-Related Macular Degeneration: Developing Drugs for Treatment. Guidance for Industry","author":"Food and Drug Administration","year":"2023","unstructured":"Food and Drug Administration. Neovascular Age-Related Macular Degeneration: Developing Drugs for Treatment. Guidance for Industry. Food and Drug Administration; 2023 March. FDA-2022-D-0073."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1102673"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.03.053"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2014.1019"},{"issue":"5","key":"e_1_3_3_7_2","first-page":"195","article-title":"Long-term results of treatment of neovascular age-related macular degeneration using antiangiogenic drugs: a review of the literature","volume":"99","author":"Enr\u00edquez-Fuentes JE","year":"2024","unstructured":"Enr\u00edquez-Fuentes JE, Oribio-Quinto C, Pascual-Santiago MA, Alarc\u00f3n-Garc\u00eda AD, Fern\u00e1ndez-Vigo JI. Long-term results of treatment of neovascular age-related macular degeneration using antiangiogenic drugs: a review of the literature. Arch Soc Esp Oftalmol (Engl Ed). 2024;99(5):195-204.","journal-title":"Arch Soc Esp Oftalmol (Engl Ed)"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2024.08.022"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.02.027"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.05.028"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-198909030-00001"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.opx.0000187863.12609.7b"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2014.04.004"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000003774"},{"key":"e_1_3_3_15_2","unstructured":"Center for Preventative Ophthalmology and Biostatistics. Comparison of Age-Related Macular Degeneration Treatment Trials (CATT). University of Pennsylvania Perelman School of Medicine. https:\/\/www.med.upenn.edu\/cpob\/catt.html"},{"key":"e_1_3_3_16_2","unstructured":"R Core Team (2024). _R: A Language and Environment for Statistical Computing_. R Foundation for Statistical Computing Vienna Austria. 2024; RStudio Team. RStudio: Integrated Development for R. RStudio PBC Boston MA. 2020; Wickham H Hester J Bryan J. _readr: Read Rectangular Text Data_. 2024; Ooms J. _writexl: Export Data Frames to Excel \u2018xlsx\u2019 Format_. 2024; Auguie B. _gridExtra: Miscellaneous Functions for \u201cGrid\u201d Graphics. 2017; H. Wickham. ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag New York 2016."},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2004.049726"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2005.073643"}],"container-title":["Journal of VitreoRetinal Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264261472092","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/24741264261472092","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264261472092","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:24:20Z","timestamp":1790695460000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/24741264261472092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":17,"alternative-id":["10.1177\/24741264261472092"],"URL":"https:\/\/doi.org\/10.1177\/24741264261472092","relation":{},"ISSN":["2474-1264","2474-1272"],"issn-type":[{"value":"2474-1264","type":"print"},{"value":"2474-1272","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"article-number":"24741264261472092"}}